Merck & Co., Inc. Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Merck & Co., Inc. (MRK).

Back to Analysis Hub

Give me a comprehensive price target analysis for Merck & Co., Inc. (MRK).

Horizontal price targets drawn and extended

  • Low Target: 82.00 (extended to 2025-11-09)
  • Median Target: 98.00 (extended to 2025-11-09)
  • High Target: 137.00 (extended to 2025-11-09)

Drawing summary:

  • Low: MRK line in blue (#1E90FF) at 82.00, from 2025-10-10 to 2025-11-09
  • Median: MRK line in orange (#FFA500) at 98.00, from 2025-10-10 to 2025-11-09
  • High: MRK line in orange-red (#FF4500) at 137.00, from 2025-10-10 to 2025-11-09

Technical note: Lines were plotted on the active MRK chart with 30 days of forward extension as requested.

Comprehensive price target analysis for Merck & Co., Inc. (MRK) Date of analysis: 2025-10-10

Executive Summary

  • MRK trades at a value-oriented multiple with a robust dividend yield and a solid balance sheet, supported by a conservative forward multiple and strong profitability metrics.
  • The current price (87.5) sits above the conservative Low target (82) and below the Median target (98) and High target (137). There is meaningful upside to consensus targets, with potential upside to mean/median targets in the mid-teens to low-20s over the next 12-24 months and a substantial upside if growth catalysts materialize.
  • The market appears to be pricing in a modest growth path, with the forward P/E around 9.31 and a forward-looking setup supported by solid margins, ROE around 35%, and a dividend yield of 3.75%.

Fundamental Analysis

  • Key valuation metrics
    • Current price: 87.50
    • Market cap: $218.56B
    • Enterprise value: $242.66B
    • Trailing P/E: 13.48
    • Forward P/E: 9.31
    • Price to book: 4.47
    • PEG: not provided (no explicit PEG; growth is implied via forward earnings)
    • ROE: 35.42%
    • ROA: 13.01%
    • Net profit margin: 25.79%
    • Gross margin: 77.41%
    • Operating margin: 37.47%
    • Debt/Equity: 72.16%
    • Total cash: $8.62B
    • Total debt: $35.40B
    • Dividend yield: 3.75%
    • Five-year avg dividend yield: 3.04%
    • Beta: 0.373 (low-beta profile; relatively defensive)
  • Balance sheet and cash flow context
    • Cash on hand modest relative to gross debt, implying a net debt position, but leverage is manageable within the sector for a large cap with strong cash flow generation.
    • Profitability and margins are robust, with healthy gross and operating margins and a strong ROE signal, which supports earnings resilience.
  • Implication: MRK remains attractively valued on a forward basis, offering a high-quality earnings base, attractive cash generation, and a dependable dividend, though leverage requires ongoing monitoring.

Earnings Analysis

  • Recent earnings performance (selected highlights from the provided quarterly data)
    • 2025-06-30 quarter:
      • Normalized Income: $4.9035B
      • EBITDA: $6.423B
      • Operating Income: $5.552B
      • Net Income (continuing ops): $4.427B
      • Diluted EPS: $1.76
      • Total Revenue: $15.806B
    • The quarter shows solid profitability with normalization factors excluding unusual items, consistent with MRK’s history of strong operating performance.
  • EPS Trends
    • Trailing/period shows near-term EPS in the low- to mid-2s per quarter (0q: 2.358; +1q: 2.212). The year-over-year perspective shows a higher trailing 12-month EPS (0y: 8.929; +1y: 9.588), indicating continued earnings strength when aggregating four quarters.
    • The longer-term EPS trend (0y vs +1y) suggests modest growth expectations across the next year.
  • EPS Revisions
    • 0q: down revisions appeared in the last 30 days (downLast30days: 1; downLast7Days: 1)
    • +1q: similar pattern (downLast30days: 1; downLast7Days: 1)
    • 0y: more negative revisions occurred in the last 30 days (downLast30days: 2; downLast7Days: 2)
    • +1y: one-up revision observed (upLast7Days: 1; upLast30Days: 1)
    • Interpretation: Near term sentiment had some downward revisions, but longer horizon (~+1y) revisions show a glimmer of positive sentiment. The revisions data suggests modest recalibration rather than a severe shift in earnings trajectory.
  • Earnings quality
    • Revenue around $15.8B for the recent quarter with stable margins and positive operating income indicate earnings quality supported by core operations.
    • Normalized EBITDA of ~$6.4B in the latest quarter suggests healthy operating cash flow potential to support both dividends and debt service.

Technical Analysis

  • Price action and trend indicators
    • Current price: 87.5
    • 50-day moving average (latest): 82.7 (as of 2025-10-09)
    • Price vs. 50-day MA: Price is above the 50-day MA, indicating near-term bullish momentum and a positive short-term trend.
    • RSI (14): 64.1 (mid-to-upper range, not yet overbought; supports continued upside with controlled risk)
    • MACD (12,26,9): Positive and above the signal line (MACD ~1.6 vs Signal ~0.9 as of 2025-10-09)
  • Key support/resistance context
    • Immediate near-term support sits around MRK’s 50-day MA (~82.7), with the stock currently trading above that level.
    • The recently drawn horizontal lines mark target levels at 82 (low), 98 (median), and 137 (high); the price is closer to the low and midpoint levels than to the high, suggesting a favorable risk/reward if the stock elevates toward mid-to-high targets.
  • Moving averages and momentum
    • 50-day MA rising toward price action supports a constructive intermediate trajectory.
    • RSI not yet in overbought territory; MACD positive indicates ongoing upside potential with room to run before potential pullbacks.
  • Implication: Technical setup is constructive, with upside potential toward the median target (98) and beyond, while the 82 support line provides a downside cushion.

Analyst Consensus & Price Targets

  • Current consensus snapshot
    • Current price: 87.50
    • Number of analysts covering MRK: 25
    • Target high price: 137.00
    • Target low price: 82.00
    • Target median price: 98.00
    • Target mean price: 101.44
  • Implied upside from current price
    • To median target (98): +11.9% approximately
    • To mean target (101.44): +15.9% approximately
    • To high target (137): +56.6% approximately
  • Interpretation: The consensus range implies meaningful upside potential, with a broad upside scenario if favorable catalysts materialize, though there is a wide dispersion between the low and high targets.

Price Target Analysis (Short, Mid, Long-Term)

  • Short-Term (3 months)
    • Target: 98.0
    • Justification: Positive earnings momentum, supportive forward multiple, and a constructive technical setup (price above 50-day MA; RSI in the 60s; MACD positive). The stock trading above the 50-day MA lends itself to near-term upside toward the median target.
    • Key drivers: Stable profitability, dividend support, modest earnings revisions with some near-term caution but upside potential from pipeline news and macro stability.
    • Upside potential vs current: ~12%
    • Risks: Near-term profit-taking, macro market risk, regulatory/pipeline setbacks.
  • Mid-Term (12 months)
    • Target: 98.0 (median) or 101.4 (mean) as a realistic midpoint
    • Justification: Gradual earnings growth supported by a robust product portfolio, ongoing pipeline milestones, and accretive capital allocation. Valuation remains reasonable with forward P/E around 9.3.
    • Key drivers: Pipeline progress (oncology, vaccines), price growth in core franchises, cost discipline, and potential share repurchases/dividend actions.
    • Upside potential vs current: ~12–16% to median/mean targets
    • Risks: Competitive dynamics (biosimilars in some segments), patent cliffs for individual assets, and payer dynamics.
  • Long-Term (3+ years)
    • Target: 137.00
    • Justification: If MRK sustains growth in vaccines, oncology, and other high-margin segments, combined with continued deleveraging and capital allocation efficiency, a multi-year growth path could realize higher gains. The implied upside to 137 reflects a scenario of sustained earnings growth, multiple expansion, and successful monetization of pipeline milestones.
    • Key drivers: Durable free cash flow, dividend growth, potential strategic acquisitions, and expanded addressable markets in vaccines and oncology.
    • Upside potential vs current: ~56%+ (to 137)
    • Risks: Longer-term uncertainty around competition, regulatory shifts, and changes in payer dynamics; macro headwinds may temper multiple expansion.

Key Risks & Opportunities

  • Major risks
    • Pipeline risk: Clinical trial failures or slower-than-expected approvals for high-priority assets.
    • Competition and biosimilars: Keytruda and other products facing biosimilar pressure could erode margins and market share over time.
    • Patent cliffs and pricing pressure: Long-term revenue dynamics could be affected by patent expirations and pricing reforms.
    • Debt and leverage: While cash flow is robust, the debt load warrants ongoing management, particularly in a rising rate environment.
  • Key opportunities
    • Dividend + buybacks: MRK’s yield and capital return programs add to total return potential.
    • Pipeline upside: Strong potential from vaccines and oncology programs, including combinations and new indications.
    • Pricing power and margin expansion: Continued efficiency improvements could sustain high operating margins and ROE.

Investment Recommendation

  • Recommendation: Buy (with a 12–24 month horizon)
  • Rationale: The stock features a solid earnings base, strong profitability, and a forward P/E around 9.3. The current price sits above the low target and below the median/high consensus targets, implying meaningful upside potential if the company meets or modestly surpasses earnings and pipeline milestones. The dividend yield of 3.75% enhances total returns, and the beta is modestly low, offering some downside protection relative to broader equities.
  • Expected return potential over 12–24 months: Approximately 12–16% to the median/mean targets, with a potential upside to ~56% if high-end targets are realized and multiple expansion occurs. A conservative scenario would see ~12–16% annualized upside, with higher upside contingent on catalysts (clinical milestones, approvals, pipeline performance, and capital allocation effectiveness).
  • Time horizon: 12–24 months

Key tables (selected numerical data)

  • Valuation and fundamentals
    • Current price: 87.50
    • Market cap: $218.56B
    • EV: $242.66B
    • Trailing P/E: 13.48
    • Forward P/E: 9.31
    • P/B: 4.47
    • ROE: 35.42%
    • ROA: 13.01%
    • Net profit margin: 25.79%
    • Gross margin: 77.41%
    • Operating margin: 37.47%
    • Debt/Equity: 72.16%
    • Total cash: $8.62B
    • Total debt: $35.40B
    • Dividend yield: 3.75%
    • Five-year avg dividend yield: 3.04%
    • Beta: 0.373
  • Analyst targets
    • Current price: 87.50
    • Number of analysts: 25
    • Target low: 82.00
    • Target median: 98.00
    • Target mean: 101.44
    • Target high: 137.00

Note on data sources used

  • Price targets and analyst consensus data are taken from the provided “Analyst Price Targets” section.
  • Earnings snapshot and EPS figures are drawn from the “Recent Earnings Summary,” “EPS Trend,” and “EPS Revisions” data.
  • Technical indicators (50-day MA, RSI, MACD) are taken from the provided “Technical Indicators (Last 60 Days)” sections.
  • The horizontal lines drawn on the MRK price chart reflect the Low (82.00), Median (98.00), and High (137.00) targets and are extended to 2025-11-09 (30 days forward from 2025-10-10), per your drawing instructions.

If you’d like, I can add a sensitivity analysis showing implied returns under alternative scenarios (e.g., beat/mmiss on earnings, pipeline milestones, or multiple expansion/shrink scenarios) and include a probabilistic view around the 12–24 month outlook.

Chart is loading...